Market Trends and Dynamics The global hematuria treatment market is anticipated to experience a consistent compound annual growth rate (CAGR) in terms of revenue during the forecast period. Key factors propelling the growth of market revenue include a high prevalence of conditions like Urinary Tract Infection (UTI) and kidney stones, as well as an increase in hematuria cases among adults.

Although the presence of blood in urine doesn't always indicate illness, it serves as a crucial warning sign of potential health issues. Urine with blood should not be overlooked. The treatment of hematuria largely depends on its underlying cause. The recommended antibiotics for treatment may vary based on the specific part of the urinary tract being treated. Nevertheless, advancements in drug delivery methods and concentrations allow for the prevention of infection or illness at the cellular and molecular levels.

Competitive Landscape Organic and Inorganic Strategies Adopted:

• In 2019, the FDA approved Recarbrio (imipenem, cilastatin, and relebactam) to treat complex urinary tract infections (cUTI) and difficult intra-abdominal infections (cIAI).
• In February 2020, a French pharmaceutical company launched Exblifep, a combination of a new extended-spectrum beta-lactamase inhibitor, enmetazobactam, and cefepime, specifically for complex UTIs.
• In April 2021, the FDA authorized Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular mortality, and hospitalization for heart failure in individuals with chronic kidney disease at risk of disease progression.
• In April 2018, Otsuka Pharmaceutical Co., Ltd. announced that JYNARQUE (tolvaptan) was FDA-approved as the first drug therapy to halt kidney function decline in people at risk of fast-progressing autosomal dominant polycystic kidney disease.

Get a sample copy of the Hematuria Treatment Market report: https://www.reportsanddata.com/download-free-sample/5277

As per the International Incontinence Society, 70% to 80% of adults above the age of 80 exhibit symptoms of an Overactive Bladder. Hematuria's prevalence increases with age, with those over 35 being more susceptible to hematuria symptoms.

Hematuria can result from various clinical conditions, with Chronic Kidney Disease (CKD) being a common and potentially fatal condition affecting a growing global population. CKD is associated with conditions like kidney stones, Glomerulonephritis, polycystic kidney disease, and urinary tract infections. Chronic kidney disease is a leading cause of hematuria. Other causes include cancer, an enlarged prostate, and kidney damage.

Factors Driving Market Growth Drivers:

• The rising prevalence of chronic diseases has led to increased healthcare spending, a major driver for market revenue growth. Governments in several countries are investing significantly in upgrading healthcare infrastructure. Additionally, patients in developed economies are becoming more informed about available hematuria treatments.

Restraints:

• High treatment costs lead to hesitancy among individuals in adopting suitable hematuria treatments, which acts as a major restraint to market revenue growth during the forecast period. The expiration of drug patents can pose a significant challenge for major market players. Undiscovered occurrences of related indications also limit revenue growth in the hematuria treatment market.

Opportunities:

• Extensive research and development efforts, the introduction of high-throughput screening (HTS) for drug discovery, and FDA approvals for drugs present opportunities for pharmaceutical companies to introduce innovative therapies and potential pipeline medications. Moreover, there is room for expanding related treatments, particularly in emerging nations, offering substantial growth prospects for hematuria treatment market participants.

Geographic Market Landscape Largest Market Share:

• North America is expected to hold the largest revenue share during the forecast period due to early acceptance of branded products, favorable healthcare reimbursement policies, recent FDA approvals, a substantial pipeline of medications, and a focus on reducing untreated hematuria cases through early treatment. The societal cost of UTI infections, including healthcare expenses and lost work time, is estimated to be over USD 3.5 billion per year in the U.S. alone.

Fastest Growing Region:

• Asia Pacific is anticipated to register a significant revenue CAGR in the forecast period due to the increasing prevalence of chronic diseases and substantial healthcare spending increases. Governments of several countries are investing in modernizing healthcare infrastructure. Hematuria serves as an early symptom of chronic illnesses such as blood cancer, bladder cancer, and kidney cancer, which are covered by various health insurance policies, easing patient treatment and reducing healthcare financial burdens. Improved healthcare spending and patient awareness about treatment are driving rapid revenue growth in the Asia Pacific hematuria treatment market.

Key Market Trends and Innovations With the rising prevalence of hematuria, the demand for advanced treatments is expected to increase. For example, a 2020 article published in ScienceDirect discusses the study of Tranexamic acid intraprostatic injection to reduce refractory bleeding while preserving therapeutic anticoagulation, which could significantly boost market revenue if approved.

Major Companies in the Market Include:

• Pfizer, Inc.
• Johnson & Johnson
• F. Hoffmann La Roche Ltd.
• AstraZeneca plc
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim GmbH
• Merck & Co.
• GlaxoSmithKline, Inc.
• Cipla Ltd.
• Bristol Myers Squibb Company
• Novartis AG
• Sun Pharmaceutical Industries Ltd.

Market Segmentation

• Type Outlook (Revenue, USD Million; 2019-2030): Gross Hematuria, Microscopic Hematuria
• Indication Outlook (Revenue, USD Million; 2019-2030): Urinary Tract Infections, Kidney Stones, Tumors, Others
• Route of Administration Outlook (Revenue, USD Million; 2019-2030): Oral, Parenteral
• Product Outlook (Revenue, USD Million; 2019-2030): Tablets, Capsules, Injection, Others
• Distribution Channels Outlook (Revenue, USD Million; 2019-2030): Online, Offline
• End User Outlook (Revenue, USD Million; 2019-2030): Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Explore Trending Reports:

Antifreeze Proteins Market-https://www.globenewswire.com/news-release/2020/04/13/2015157/0/en/Antifreeze-Proteins-Market-To-Reach-USD-11-1-Million-By-2027-Reports-and-Data.html

Food Enzymes Market-https://www.globenewswire.com/news-release/2019/09/19/1918190/0/en/Food-Enzyme-Market-To-Reach-USD-3-80-Billion-By-2026-Reports-And-Data.html

Wheat Protein Market-https://www.globenewswire.com/news-release/2019/09/19/1918180/0/en/Wheat-Protein-Market-To-Reach-USD-3-08-Billion-By-2026-Reports-And-Data.html

Lactoferrin Market-https://www.globenewswire.com/news-release/2020/01/28/1976342/0/en/Lactoferrin-Market-To-Reach-USD-329-7-Million-By-2026-Reports-And-Data.html

Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5277

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data    

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report

Browse Latest Blogs: https://www.reportsanddata.com/blogs

Browse Latest Press Release: https://www.reportsanddata.com/press-release